Strategic partnership Kling Biotherapeutics has active collaboration with Sanofi as of July 2025 to discover antibodies and epitopes using its Kling-Select platform, signaling openness to licensing, co-development, and potential milestone-driven deals with major pharma.

Clinical-stage assets With KBA1412 in Phase I and a preclinical pipeline, there are opportunities to explore strategic investments, licensing, or research collaborations to accelerate asset progression and share development risk.

Proprietary platforms Kling-Select and Kling-Evolve enable rapid target discovery and antibody maturation from patient-derived B cells, presenting strong value for pharma partners seeking innovative antibody discovery, epitope diversity, and fast lead optimization.

Private funding signals As a privately held, Netherlands-based biotech with a revenue range of $1M-$10M, Kling Bio may be open to strategic funding, R&D collaborations, or co-development agreements to scale platform capabilities and expand the pipeline.

Global access and scale Headquartered in Amsterdam with a cloud-enabled tech stack and global potential for clinical programs, there are sales opportunities around international collaboration, technology licensing, and access to platform services across markets.